QUARTERLY REPORT Q3 2025
SIGNIFICANT EVENTS DURING 1 JULY – 30 SEPTEMBER 2025During the third quarter, Iconovo carried out a reorganization to focus on the three largest near-term…
KVARTALSRAPPORT Q3 2025
VÄSENTLIGA HÄNDELSER 1 JULI – 30 SEPTEMBER 2025Under tredje kvartalet genomförde Iconovo en omorganisation för att fokusera på de tre största möjligheterna…
QUARTERLY REPORT Q2 2025
SIGNIFICANT EVENTS DURING 1 APRIL – 30 JUNE 2025In April, Iconovo announced an organizational change expected to reduce annual costs by approximately…
KVARTALSRAPPORT Q2 2025
VÄSENTLIGA HÄNDELSER 1 APRIL – 30 JUNI 2025I april meddelade Iconovo en organisationsförändring som beräknas reducera kostnadsmassan med cirka 14–16…
Correction: ICONOVO AB PUBLISHES THE ANNUAL REPORT 2024 IN ENGLISH
Wrong annual report initially attached to this press release; hereby corrected.
The abbreviated annual report 2024 in English is attached to this press…
ICONOVO AB PUBLISHES THE ANNUAL REPORT 2024 IN ENGLISH
The abbreviated annual report 2024 in English is attached to this press release and is now available on the company's website, www.iconovo.se.
ContactsJohan Wäborg,…
ICONOVO AB PUBLICERAR ÅRSREDOVISNING FÖR 2024
Årsredovisningen bifogas i detta pressmeddelande och finns nu tillgänglig på företagets webbplats, www.iconovo.se.
KontakterJohan Wäborg, VD+46 707…
QUARTERLY REPORT Q1 2025
SIGNIFICANT EVENTS DURING 1 JANUARY – 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal…
KVARTALSRAPPORT Q1 2025
VÄSENTLIGA HÄNDELSER 1 JANUARI – 31 MARS 2025Iconovo och Lonza har inlett ett samarbete för att utveckla spraytorkade formuleringar av ett intranasalt…
Year-end report 1 January – 31 December 2024
27 February 2025
